Newsroom

Zellen von Listeria monocytogenes
News
Liver cancer is the third most common cause of cancer-related deaths worldwide. So far, the treatment options for two types of liver cancer, hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), have been inadequate, while the number of new cases has been rising. A study by researchers at the Hannover Medical School (MHH) and the Helmholtz Centre for Infection Research (HZI) now offers hope. A vaccine based on a highly attenuated infectious agent called Listeria monocytogenes proved to be safe and effective protection in premalignant and malignant liver diseases in preclinical mouse models.
18.02.2022
3D-Illustration eines Monozyten
News
An international research team from TWINCORE - Centre for Experimental and Clinical Infection Research, a joint facility of the Helmholtz Centre for Infection Research (HZI) in Braunschweig and the Hannover Medical School, describes the dual effect of the endogenous substance itaconic acid, which is both antiviral and anti-inflammatory. Their study, which has now appeared in the journal PLoS Pathogens, opens up perspectives for possible therapeutic applications of itaconic acid against severe courses of disease in viral infections. 
17.02.2022
Fruchtkörper von Myxobakterien unter dem Lichtmikroskop
News
Pharma-backed incubator INCATE selected the HZI start-up project Myxobiotics as one of the first start-ups to get support. Myxobiotics develops a new class of antibiotics against Acinetobacter baumannii, which causes severe, difficult-to-treat respiratory infections. Myxobiotics’ approach is based on a new class of natural compounds (cystobactamids) discovered and developed as antibacterial agents by Prof Rolf Müller and Prof Mark Brönstrup and their teams at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and Helmholtz Centre for Infection Research (HZI), together with Dr Thomas Hesterkamp and Evotec. The HIPS is a site of the HZI in collaboration with Saarland University.
04.02.2022
 Prof. Dirk Heinz und Stephan Weil
News
The Minister President of Lower Saxony, Stephan Weil, visited the Helmholtz Centre for Infection Research (HZI) today, 4 February 2022. The visit focused on the current challenges and innovative approaches, especially in combating the SARS-CoV-2 pandemic, and the future development of infection research in Lower Saxony. He also delivered a message of thanks to the scientists at the research centre in Braunschweig.
04.02.2022
Zytomegalievirus
News
Viruses are mostly encountered as pathogens. However, virus-based vaccination platforms can also help to provide protection from different diseases. In a mouse model, researchers from the Helmholtz Centre for Infection Research (HZI) in Braunschweig together with national and international partners including the German Center for Infection Research (DZIF), the German Primate Center – Leibniz Institute for Primate Research (DPZ), the Technische Universität Braunschweig and the University of Rijeka, Croatia, have developed a novel cytomegalovirus-based vaccine against different respiratory viruses. A single dose of the vaccine that consists of a cytomegalovirus that incorporates genes from coronavirus or influenza A efficiently protected mice from the respiratory infections. The results on the vaccine candidate, which is not yet market-ready, were published in the journal Cellular & Molecular Immunity.
17.01.2022
Portrait
News
Principal Investigator Mathias Munschauer aims to better understand SARS-CoV-2. He now receives funding of 1.5 million euros for his research project “COVIDecode” from the European Research Council (ERC). Munschauer is the third scientist at the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg to be awarded an ERC grant.
10.01.2022

HZI in the media

... Medizinischen Hochschule Hannover (MHH) und des Helmholtz-Zentrums für Infektionsforschung (HZI). Dafür setzten die Forschenden sechs ...

19.08.2026
|
Pharmazeutische Zeitung

available genomic resources. HIPS is a site of the Helmholtz Centre for Infection Research (HZI) in collaboration with Saarland University.

14.08.2026
|
News Medical

... verfügbaren genomischen Ressourcen erheblich. HIPS ist ein Standort des Helmholtz-Zentrums für Infektionsforschung in Zusammenarbeit ...

12.08.2026
|
DeutschesGesundheitsPortal

... nennen wären da zum Beispiel das Helmholtz-Zentrum für Infektionsforschung oder aber das Deutsche Zentrum für ...

11.08.2026
|
news38

Ein Forschungsteam am Helmholtz-Institut für Pharmazeutische Forschung Saarland (HIPS) hat nun eine Reihe synthetischer ...

07.08.2026
|
ZMK - Zahnheilkunde Management Kultur

des HIRI kooperieren hierbei mit dem Helmholtz-Zentrum für Infektionsforschung (HZI) und dem Helmholtz-Institut für One Health (HIOH). Ein

06.08.2026
|
Börse Express

... beschleunigen

 

Das DFKI hat zusammen mit dem Helmholtz-Institut für Pharmazeutische Forschung Saarland (HIPS), der ...

02.08.2026
|
SR Saarländischer Rundfunk

... Forschungszentrum Fahrzeugtechnik (NFF) oder dem Helmholtz-Zentrum für Infektionsforschung (HZI).

 

Am 24. März 19973 ...

01.08.2026
|
t-online.de

... including to Germany, for further testing. Professor Fabian Leendertz at the Helmholtz Institute for One ...

31.07.2026
|
Deutsche Welle

Spannend: Am Exponat des Helmholtz-Instituts Saarland kann man nach Bodenbakterien suchen. | Foto: Ilja C. ...

30.07.2026
|
Die Rheinpfalz

Sprachmodellen und Einzelzellanalysen bei, das Helmholtz-Institut für Pharmazeutische Forschung Saarland übernimmt die chemische Synthese ...

29.07.2026
|
Deutsches Ärzteblatt

... in Wirkstoffdesign, Sprachmodellen und Einzelzellanalysen bei, das Helmholtz-Institut für Pharmazeutische Forschung Saarland ( HIPS ) ...

24.07.2026
|
Management & Krankenhaus

Register now for the HZI newsletter